3 research outputs found
Diseño de un dinamómetro que permita la medición, registro y almacenamiento de datos para fuerza de agarre
Las enfermedades músculo esqueléticas, en la mayorÃa de los casos, son el resultado de un deterioro
progresivo generado por microtraumatismos asociados a movimientos repetitivos y posturas
forzadas, cuyas causas se han relacionado con diferentes factores, entre ellos, el trabajo. Este tipo
de trastornos provocan dolor y fatiga muscular disminuyendo la calidad de vida de las personas, y se
han convertido en un problema de salud pública a nivel nacional e internacional. Por otro lado, la
fuerza de agarre es la medida de la máxima fuerza posible realizada voluntariamente por parte de
una persona y combina la interacción de músculos intrÃnsecos y extrÃnsecos que permiten el
movimiento de las extremidades superiores. El instrumento empleado para medir este tipo de fuerza
es el dinamómetro de mano, agarre o empuñadura, y algunas investigaciones realizadas alrededor
del mundo concluyen que la medición de la fuerza de agarre puede ser utilizada como referencia
para la prevención y control de enfermedades músculo esqueléticas. Por lo anterior, se propone el
diseño de un dinamómetro que permita medir fuerza de agarre en la mano y almacenar los registros
en una base de datos para su posterior análisis a partir de estadÃsticos y gráficas. Esto con el fin de
que sea utilizado en el ámbito laboral, por parte del área de seguridad y salud en el trabajo, como
una referencia para la toma de decisiones que favorezcan el bienestar de los empleados por medio
de la prevención y control de trastornos musculoesqueléticos.Musculoskeletal diseases are, in most of the cases, product of a progressive deterioration generated
by micro traumatisms associated to repetitive movements and strained positions which causes are
related to diverse factors, including work. These conditions lead to fatigue and ongoing muscle pain
for the individual, carrying his life quality to lower levels, which is one of the reasons why these
have become a major public health issue worldwide. On the other hand, grip strength is the measure
of the maximum possible force intentionally imprinted by a person, combining inner and outer
muscle interactions that allow movement on the upper extremities. The instrument used to measure
this type of force is called handgrip dynamometer, and some researchers from around the globe
evidence how grip strength can be used as a reference to prevent and control musculoskeletal
diseases. Therefore, the present project proposes the design of a dynamometer that allows the
measurement and recording of handgrip strength in a database where they can be accessed for their
analysis using charts and statistics. This, in order to be used in companies, by the health and safety
at work department, to ease decision-making favoring employees welfare.Ingeniero (a) IndustrialPregrad
Efficacy of the mHealth application in patients with type 2 diabetes transitioning from inpatient to outpatient care: A randomized controlled clinical trial
Introduction: No studies have assessed the efficacy of telemedicine using a platform for recording and adjusting insulin doses in patients with diabetes mellitus type 2 (DM2) transitioning from inpatient to outpatient care. This study aimed to assess, in a population of patients with DM2, discharged from a tertiary referral hospital, whether treatment based on the use of an mHealth application was associated with better glycemic control at the 3-month follow-up, than standard care.
Methods: This open, randomized, controlled clinical trial included adult DM2 patients who were transitioning from inpatient to outpatient care. The efficacy and safety of patient management with and without mHealth was compared at the 3-month follow-up. The primary outcome was the change in the Glycosylated hemoglobin (HbA1c) levels. The secondary outcomes were the rates of hypoglycemic and hyperglycemic events and treatment satisfaction measured using the Insulin Treatment Satisfaction Questionnaire (ITSQ).
Results: In total, 86 patients (41 using mHealth) were included in the clinical trial. HbA1c levels showed a significant decrease in both groups. The mean HbA1c level was significantly lower in the mHealth group. Patients using mHealth showed decreased incidence rate ratios of hypoglycemia 3.0 mmol/L [<54 mg/dl], hypoglycemia ranging from 3.0 to 3.8 mmol/L [54 to 70 mg/dl] and severe hypoglycemia. The level of satisfaction assessed using the ITSQ was higher in the mHealth group.
Conclusion: Using mHealth in patients with DM2 transitioning from inpatient to outpatient care improves metabolic control and may reduce the hypoglycemia rates
Efficacy of the mHealth application in patients with type 2 diabetes transitioning from inpatient to outpatient care : a randomized controlled clinical trial
Ningún estudio ha evaluado la eficacia de la telemedicina utilizando una plataforma para registrar y ajustar las dosis de insulina en pacientes con diabetes mellitus tipo 2 (DM2) en transición de atención hospitalaria a ambulatoria . Este estudio tuvo como objetivo evaluar, en una población de pacientes con DM2, dados de alta de un hospital de referencia de tercer nivel, si el tratamiento basado en el uso de una aplicación mHealth se asoció con un mejor control glucémico a los 3 meses de seguimiento, que la atención estándar.
Métodos
Este ensayo clÃnico abierto, aleatorizado y controlado incluyó a pacientes adultos con DM2 que estaban pasando de la atención hospitalaria a la ambulatoria. Se comparó la eficacia y seguridad del manejo de pacientes con y sin mHealth en el seguimiento de 3 meses. El resultado primario fue el cambio en los niveles de hemoglobina glicosilada (HbA1c). Los resultados secundarios fueron las tasas de eventos hipoglucémicos e hiperglucémicos y la satisfacción con el tratamiento medida mediante el Cuestionario de Satisfacción con el Tratamiento con Insulina (ITSQ).
Resultados
En total, se incluyeron en el ensayo clÃnico 86 pacientes (41 con mHealth). Los niveles de HbA1c mostraron una disminución significativa en ambos grupos. El nivel medio de HbA1c fue significativamente más bajo en el grupo mHealth. Los pacientes que usaban mHealth mostraron Ãndices de tasa de incidencia reducidos de hipoglucemia de 3,0 mmol/L [<54 mg/dl], hipoglucemia que oscilaba entre 3,0 y 3,8 mmol/L [54 a 70 mg/dl] e hipoglucemia grave. El nivel de satisfacción evaluado mediante el ITSQ fue mayor en el grupo mHealth.
Conclusión
El uso de mHealth en pacientes con DM2 en transición de atención hospitalaria a ambulatoria mejora el control metabólico y puede reducir las tasas de hipoglucemia.Q1No studies have assessed the efficacy of telemedicine using a platform for recording and adjusting insulin doses in patients with diabetes mellitus type 2 (DM2) transitioning from inpatient to outpatient care. This study aimed to assess, in a population of patients with DM2, discharged from a tertiary referral hospital, whether treatment based on the use of an mHealth application was associated with better glycemic control at the 3-month follow-up, than standard care.
Methods
This open, randomized, controlled clinical trial included adult DM2 patients who were transitioning from inpatient to outpatient care. The efficacy and safety of patient management with and without mHealth was compared at the 3-month follow-up. The primary outcome was the change in the Glycosylated hemoglobin (HbA1c) levels. The secondary outcomes were the rates of hypoglycemic and hyperglycemic events and treatment satisfaction measured using the Insulin Treatment Satisfaction Questionnaire (ITSQ).
Results
In total, 86 patients (41 using mHealth) were included in the clinical trial. HbA1c levels showed a significant decrease in both groups. The mean HbA1c level was significantly lower in the mHealth group. Patients using mHealth showed decreased incidence rate ratios of hypoglycemia 3.0 mmol/L [<54 mg/dl], hypoglycemia ranging from 3.0 to 3.8 mmol/L [54 to 70 mg/dl] and severe hypoglycemia. The level of satisfaction assessed using the ITSQ was higher in the mHealth group.
Conclusion
Using mHealth in patients with DM2 transitioning from inpatient to outpatient care improves metabolic control and may reduce the hypoglycemia rates.Revista Internacional - IndexadaS